Clinical trial NCT01614210: Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
Official title: Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2012-06-07
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.

Detailed description: Patients who are eligible (newly diagnosed hormone positive clinical stage 1 or 2 breast cancer) will be approached about the study. If they sign informed consent a prescription for 21 doses of Tamoxifen will be provided. The patient's surgery will be scheduled at a time convenient for the patient and the surgeon. Once the surgery has been scheduled, a medication calendar will be completed that allows the patient to take tamoxifen for 7 days preoperatively with the 7th dose of tamoxifen to coincide with the day before surgery. The patient will continue to take tamoxifen for 2 weeks (14 days) after surgery. Patients will then proceed along normal treatment guidelines. For those needing chemotherapy or radiation therapy, we recommend the long term endocrine therapy start at the conclusion of chemo and/or radiation treatments. For those not going on to any additional therapy, the prescription for endocrine therapy will be written at the initial post-operative visit.

Unstained slides from the formalin-fixed, paraffin-embedded tissue blocks from the patient's breast tissue from which the original diagnosis of breast cancer was made by H\&E will be stained for Ki67. After endocrine therapy and subsequent resection, carcinoma will be confirmed by the participating pathologist on H\&E, and Ki67 will be performed on unstained slides from a representative tissue block containing invasive carcinoma. The pathologist will circle a designated area of tumor on the H\&E slide and both the H\&E and immunostained (Ki67) slides will be scanned in a digital imaging device (Aperio XT Scanscope), which quantitatively analyzes the tumor designated by the pathologist with image analysis algorithms. The algorithm accurately detects regions of interest and distinguishes cells and sub-cellular objects within these target regions. It determines morphology and expression profiles per individual cell or cell compartment. For Ki67 analysis, a nuclear Immunohistochemistry (IHC) algorithm will be used.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Diagnosed with hormone receptor positive invasive breast cancer (estrogen receptor (ER) or progesterone receptor (PR) or both \>1%) by core needle biopsy
* Clinical American Joint Committee on Cancer (AJCC) 7th edition Stage 1 or 2
* Candidate for surgical therapy
* Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2
* No chemotherapy or endocrine therapy for breast cancer in last 5 years
* Paraffin fixed core needle tissue block, or biopsy punch available for central analysis for proliferative markers
* Not pregnant or lactating and practicing adequate birth control if premenopausal
* Able and willing to provide informed consent

Exclusion Criteria:

* Prior personal history of uterine cancer
* Prior personal history of stroke or deep vein thrombosis (DVT)
* Current therapy with strong CYP2D6 inhibitors The following medications should not be administered with tamoxifen (21 day treatment period) and will need to be stopped for the designated period of time prior to starting the study tamoxifen.

No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years

Fluoxetine - should be discontinued 30 days prior to starting tamoxifen Paroxetine - should be discontinued 5 days prior to starting tamoxifen Sertraline - should be discontinued 5 days prior to starting tamoxifen Bupropion - should be discontinued 5 days prior to starting tamoxifen

* Concurrent coumarin-type anticoagulation therapy
* Any other contraindications to tamoxifen therapy

Primary outcomes:
measure: Change in Ki67 Expression in Tumors
timeFrame: 7 days
Secondary outcomes:
measure: Change in FACT-ES Symptom Scores
timeFrame: 18 months
measure: Number of Participants With Long Term Endocrine Therapy Adherence
timeFrame: 18 months
measure: Correlation Between Changes in Ki67 and Symptoms
timeFrame: 7 days
Other outcomes:
measure: Change in FACT-ES Symptom Scores
timeFrame: 7 days
Locations:
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
Study officials:
affiliation: Huntsman Cancer Institute
name: Leigh Neumayer, MD
role: PRINCIPAL_INVESTIGATOR
References: